MedTrace Logo

Biomarkers for Risk Stratification in Lung Cancer

NCT03774758 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 590

Last updated 2025-03-20

No results posted yet for this study

Summary

This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco General Hospital. The proposed study will comprise of two primary populations to determine the ctDNA assay performance in a variety of clinical settings.

Conditions

Interventions

DIAGNOSTIC_TEST

Guardant Health ct-DNA LUNAR assay

Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease.

Sponsors & Collaborators

Principal Investigators

  • Mehrdad Arjomandi, M.D. · University of California, San Francisco

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-17
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03774758 on ClinicalTrials.gov